Botanix Pharmaceuticals
Perth
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a pharmaceutical company that focuses on the treatment of skin diseases. Its mission is to improve the lives of patients battling acne, psoriasis, and atopic dermatitis by providing new treatment options for conditions that are currently inadequately addressed or are treated with therapeutics that are burdened with side effect profiles. The company is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which is currently being studied for the treatment of epilepsy, pain, arthritis, and schizophrenia, amongst other indications. Botanix is preparing for human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (PermetrexTM) for direct skin delivery of the therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $82.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2025)
- Ticker: asx:BOT
- Website: botanixpharma.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/botanix-pharmaceuticals-212634 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.